Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone

PHASE4CompletedINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Heart FailureVentricular Dysfunction, Left
Interventions
DRUG

Captopril

DRUG

Enalapril

DRUG

Lisinopril

DRUG

Ramipril

DRUG

Trandolapril

DRUG

Bisoprolol

DRUG

Carvedilol

DRUG

Metoprolol succinate

DRUG

Candesartan

DRUG

Valsartan

DRUG

Eplerenone

DRUG

Spironolactone

DRUG

Diuretics

DRUG

HF treatment according to Swedish guidelines

PROCEDURE

Blood samples

PROCEDURE

The Kansas City Cardiomyopathy Questionnaire (KCCQ)

Trial Locations (39)

Unknown

Research Site, Alvesta

Research Site, Arvika

Research Site, Bjuv

Research Site, Borensberg

Research Site, Bromma

Research Site, Dalby

Research Site, Eskilstuna

Research Site, Gagnef

Research Site, Gothenburg

Research Site, Hisings Kärra

Research Site, Huddinge

Research Site, Huskvarna

Research Site, Jönköping

Research Site, Kalmar

Research Site, Kungälv

Research Site, Lerum

Research Site, Lessebo

Research Site, Lidköping

Research Site, Lilla Edet

Research Site, Linköping

Research Site, Ludvika

Research Site, Lyckeby

Research Site, Malmo

Research Site, Moheda

Research Site, Motala

Research Site, Örebro

Research Site, Östersund

Research Site, Skanör

Research Site, Söderåkra

Research Site, Stenungsund

Research Site, Stocksund

Research Site, Timrå

Research Site, Uddevalla

Research Site, Ulricehamn

Research Site, Umeå

Research Site, Uppsala

Research Site, Vaxjo

Research Site, Västerås

Research Site, Västervik

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY